{
    "clinical_study": {
        "@rank": "95892", 
        "acronym": "AV-X-02", 
        "arm_group": {
            "arm_group_label": "AVANZ Salsola kali", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This trial is an open, national, multi-centre trial. The trial will be initiated in December\n      2013 and subjects will receive treatment for 6 weeks.\n\n      Safety monitoring will be performed in an ongoing basis through a Clinical Safety Group with\n      immediate access to AEs registered in the clinical database. The composition, procedures and\n      deliverables of the Clinical Safety Group will be detailed in a Safety Agreement prior to\n      trial start."
        }, 
        "brief_title": "An Open Trial to Assess the Tolerability of AVANZ\u00ae Salsola Immunotherapy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis, Allergic", 
                "Conjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A clinical history of  Salsola kali pollen induced allergic rhinoconjunctivitis with\n             or without asthma at least one year prior to trial entry.\n\n          -  Positive SPT to  Salsola kali pollen (wheal diameter \u2265 3 mm).\n\n          -  Documenting in the last 5 years a positive specific IgE against  Salsola kali pollen\n             (\u2265 Class 2; \u22650.70 KU/L).\n\n        Exclusion Criteria:\n\n          -  FEV1 < 70% of predicted value at screening after adequate pharmacologic treatment.\n\n          -  Uncontrolled or severe asthma.\n\n          -  History of severe asthma exacerbation  or emergency room visit or admission for\n             asthma in the previous 12 months.\n\n          -  At screening, current symptoms of, or treatment for, upper respiratory tract\n             infection, acute sinusitis, acute otitis media or other relevant infection (serous\n             otitis media is not an exclusion criterion).\n\n          -  Treatment with parenteral corticosteroids, oral corticosteroids or anti-IgE in the\n             previous 3 months or during the study (except for steroids if needed as rescue\n             medication).\n\n          -  Currently treated with angiotensin converting enzyme (ACE) inhibitors, tricyclic\n             antidepressants, \u03b2-blockers, mono amine oxidase inhibitors (MAOIs) and any other drug\n             containing alum (e.g. antacids) taken on a daily basis.\n\n          -  Immunotherapy with Cupressus arizonica or Salsola kali pollen extracts within the\n             previous 5 years (initiation of subcutaneous immunotherapy is acceptable if treatment\n             has been discontinued before reaching maintenance dose; for SLIT 3 months in the last\n             5 years is accepted) or concomitant immunotherapy with any other allergen.\n\n          -  History of anaphylactic shock due to e.g. food, insect venom, exercise or drug.\n\n          -  History of severe and recurrent angioedema."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065856", 
            "org_study_id": "2013-001728-20", 
            "secondary_id": "2013-001728-20"
        }, 
        "intervention": {
            "arm_group_label": "AVANZ Salsola kali", 
            "intervention_name": "AVANZ Salsola kali", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "email": "gonzalez_pur@gva.es", 
                "last_name": "PURIFICACI\u00d3N GONZ\u00c1LEZ, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Alicante", 
                    "country": "Spain"
                }, 
                "name": "Hospital General Universitario de Alicante"
            }, 
            "investigator": {
                "last_name": "PURIFICACI\u00d3N GONZ\u00c1LEZ, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Trial to Assess the Tolerability of AVANZ\u00ae Salsola Immunotherapy", 
        "overall_contact": {
            "email": "SMAES@ALK.NET", 
            "last_name": "SANTIAGO MARTIN, MsC", 
            "phone": "+34913276127"
        }, 
        "overall_contact_backup": {
            "email": "PRNES@alk.net", 
            "last_name": "PILAR RICO, PhD", 
            "phone": "+34913276127"
        }, 
        "overall_official": {
            "affiliation": "HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE", 
            "last_name": "PURIFICACION GONZ\u00c1LEZ, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of patientes with adverse reactions", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for an expected average of 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065856"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Frequency of patients with systemic reactions according to  EAACI classification", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for an expected average of 6 weeks"
        }, 
        "source": "ALK-Abell\u00f3 A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ALK-Abell\u00f3 A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}